Tag Archives: biotechnology law

Novelty and Obviousness In An Empirical Research Field – The Decision of the UK Court of Appeal in Dr Reddy’s Laboratories v Eli Lilly

From Paul Cole The Lilly patent for olanzapine has been litigated in many jurisdictions including the US, Canada, the Czech Republic, Finland, Levitra order online Romania, Slovakia, Slovenia, Spain, China and Hungary. In US Court of Appeals for the Federal … Continue reading

Posted in Non-U.S. Practice | Tagged , , , , , | Leave a comment

Board Decision in Ex Parte Roberts Doesn’t Make the Cut

This 2008 pre-Bilski decision is of interest since the Board purportedly applied the Diamond v Diehr “standard” – “[t}ransformation and reduction of an article ‘to a different state or thing’ is the clue to the patentability of a process claim … Continue reading

Posted in Patenting Methods/Processes | Tagged , , , , , , , , , | Leave a comment

Federal Circuit Mows Down Bean Patent – Reading Between the Rows

On July 10, 2009, the Court of Appeals for the Federal Circuit in In re Pod-Ners, Appeal No. 2008-1492, affirmed the Board’s rejection of all of the claims of U.S. Pat. No. 5,894,079. The Board had rejected as obvious claims … Continue reading

Posted in Obviousness | Tagged , , , , , , , , , , | Leave a comment

BIO/CHEM/PHARMA CUSTOMER PARTNERSHIP CONTINUES – REPORT FROM 3/3/09 MEETING

Although this report (see link below) is of the March meeting, I hope to have current reports of meetings soon after they occur – if they continue to occur. It also gives me a chance to visit memory lane. In … Continue reading

Posted in USPTO Practice and Policy | Tagged , , , , | Leave a comment